Clinical Trial Update: Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and pharmacokinetics of HIV-neutralizing monoclonal antibodies VRC01, VRC01LS, and VRC07-523LS in HIV-1-exposed infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• VRC01 (VRC01)
• VRC01LS (VRC01LS)
• VRC07-523LS

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2021-08-23